143 related articles for article (PubMed ID: 16476675)
1. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
Sossi V; de la Fuente-Fernández R; Schulzer M; Adams J; Stoessl J
Brain; 2006 Apr; 129(Pt 4):1050-8. PubMed ID: 16476675
[TBL] [Abstract][Full Text] [Related]
2. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
4. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms.
Sossi V; de la Fuente-Fernández R; Holden JE; Schulzer M; Ruth TJ; Stoessl J
J Cereb Blood Flow Metab; 2004 Aug; 24(8):869-76. PubMed ID: 15362717
[TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
[TBL] [Abstract][Full Text] [Related]
6. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
[TBL] [Abstract][Full Text] [Related]
7. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
[TBL] [Abstract][Full Text] [Related]
8. PET studies and motor complications in Parkinson's disease.
Brooks DJ
Trends Neurosci; 2000 Oct; 23(10 Suppl):S101-8. PubMed ID: 11052227
[TBL] [Abstract][Full Text] [Related]
9. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data.
Sossi V; de La Fuente-Fernández R; Holden JE; Doudet DJ; McKenzie J; Stoessl AJ; Ruth TJ
J Cereb Blood Flow Metab; 2002 Feb; 22(2):232-9. PubMed ID: 11823721
[TBL] [Abstract][Full Text] [Related]
10. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations.
de la Fuente-Fernández R; Pal PK; Vingerhoets FJ; Kishore A; Schulzer M; Mak EK; Ruth TJ; Snow BJ; Calne DB; Stoessl AJ
J Neural Transm (Vienna); 2000; 107(1):49-57. PubMed ID: 10809403
[TBL] [Abstract][Full Text] [Related]
11. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
[TBL] [Abstract][Full Text] [Related]
12. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
Kumakura Y; Danielsen EH; Reilhac A; Gjedde A; Cumming P
Acta Neurol Scand; 2004 Sep; 110(3):188-95. PubMed ID: 15285777
[TBL] [Abstract][Full Text] [Related]
13. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
14. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Thanvi B; Lo N; Robinson T
Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
[TBL] [Abstract][Full Text] [Related]
15. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
16. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
[TBL] [Abstract][Full Text] [Related]
17. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
18. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
19. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
[TBL] [Abstract][Full Text] [Related]
20. Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
Fu JF; Matarazzo M; McKenzie J; Neilson N; Vafai N; Dinelle K; Felicio AC; McKeown MJ; Stoessl AJ; Sossi V
Mov Disord; 2021 Feb; 36(2):389-397. PubMed ID: 33090574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
